GALT (Galectin Therapeutics) Scaled Net Operating Assets: -0.44 (As of Mar. 2026)

What is Galectin Therapeutics Scaled Net Operating Assets?

Galectin Therapeutics GALT +17.83% 16 Scaled Net Operating Assets is -0.44 as of Mar. 2026. GuruFocus rates GALT with a GF Score™ of 16/100. The stock has 5 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Galectin Therapeutics's operating assets for the quarter that ended in Mar. 2026 was $1.65 Mil. Galectin Therapeutics's operating liabilities for the quarter that ended in Mar. 2026 was $10.28 Mil. Galectin Therapeutics's Total Assets for the quarter that ended in Dec. 2025 was $19.53 Mil. Therefore, Galectin Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was -0.44.

Galectin Therapeutics Scaled Net Operating Assets Related Terms

Galectin Therapeutics Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Galectin Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galectin Therapeutics Scaled Net Operating Assets Chart

Galectin Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Scaled Net Operating Assets

Get a 7-Day Free Trial

-0.27

-0.26

-0.66

-0.42

-0.58

Galectin Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Scaled Net Operating Assets	Get a 7-Day Free Trial															-0.67	-1.09	-0.93	-0.79	-0.44

GALT vs PALI, IRD, VSTM: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Galectin Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galectin Therapeutics Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galectin Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Galectin Therapeutics's Scaled Net Operating Assets falls into.

Save Embed

16GF Score

Galectin Therapeutics Inc GALT

Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Galectin Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Galectin Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2025 )
=	(Operating Assets (A: Dec. 2025 )	-	Operating Liabilities (A: Dec. 2025 ))	/	Total Assets (A: Dec. 2024 )
=	(1.812	-	11.97)	/	17.495
=	-0.58

where

	Operating Assets		(A: Dec. 2025 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	19.532	-	17.72
=	1.812

	Operating Liabilities		(A: Dec. 2025 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	145.727	-	133.735	-	0.022
=	11.97

Galectin Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Mar. 2026 )
=	(Operating Assets (Q: Mar. 2026 )	-	Operating Liabilities (Q: Mar. 2026 ))	/	Total Assets (Q: Dec. 2025 )
=	(1.648	-	10.28)	/	19.532
=	-0.44

where

	Operating Assets		(Q: Mar. 2026 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	15.759	-	14.111
=	1.648

	Operating Liabilities		(Q: Mar. 2026 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	145.996	-	135.71	-	0.006
=	10.28

Frequently Asked Questions Learn more about Scaled Net Operating Assets →

What does a Scaled Net Operating Assets of -0.44 mean?

Galectin Therapeutics (GALT) has a Scaled Net Operating Assets of -0.44 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Galectin Therapeutics and its competitors.

Is Galectin Therapeutics' Scaled Net Operating Assets too high?

Galectin Therapeutics' current Scaled Net Operating Assets is -0.44. Overall, Galectin Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.

How does Galectin Therapeutics' Scaled Net Operating Assets compare to PALI and IRD?

Galectin Therapeutics' Scaled Net Operating Assets of -0.44 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Scaled Net Operating Assets for a Biotechnology company?

A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Scaled Net Operating Assets mean?

A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Galectin Therapeutics and its competitors. Galectin Therapeutics's current Scaled Net Operating Assets is -0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Galectin Therapeutics stock overvalued right now?

Galectin Therapeutics (GALT) has a current Scaled Net Operating Assets of -0.44. The current Scaled Net Operating Assets is -0.44. Galectin Therapeutics' overall GF Score™ is 16/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Scaled Net Operating Assets calculated?

Scaled Net Operating Assets is calculated from a company's financial statements. For Galectin Therapeutics (GALT), the current Scaled Net Operating Assets is -0.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galectin Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies PALI IRD VSTM ABEO LCTX NWBO VRXA CYDY SLNCF IMRX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges PHPN:Germany

Address 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071

Website https://www.galectintherapeutics.com

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

16GF Score

Get the complete analysis for GALT

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.97

Price

View GALT Analysis

See Scaled Net Operating Assets data for all stocks →